More recent studies observed IDH1 mutations in 7% of inflammatory bowel disease-associated (IBD) CRC [134] and 11% of colitis-associated CRC [135], compared to 1% of sporadic CRC, providing a therapeutic target in these types of CRC tumors. Here, IDH1 is linked to colorectal carcinoma.